SEK 2.1
(5.53%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 162.38 Million SEK | 7.91% |
2022 | 84.98 Million SEK | -14.5% |
2021 | 99.4 Million SEK | 48.35% |
2020 | 67 Million SEK | 2020.95% |
2019 | 3.15 Million SEK | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 7.91 Million SEK | -34.92% |
2024 Q1 | 12.16 Million SEK | -52.97% |
2023 FY | 91.71 Million SEK | 7.91% |
2023 Q3 | 14.72 Million SEK | -45.47% |
2023 Q4 | 25.87 Million SEK | 75.69% |
2023 Q1 | 24.11 Million SEK | 273.44% |
2023 Q2 | 27 Million SEK | 11.99% |
2022 Q3 | 31.68 Million SEK | -12.67% |
2022 Q2 | 36.28 Million SEK | 17.32% |
2022 Q1 | 30.92 Million SEK | -31.85% |
2022 FY | 84.98 Million SEK | -14.5% |
2022 Q4 | -13.9 Million SEK | -143.88% |
2021 Q1 | 20.74 Million SEK | -42.32% |
2021 FY | 99.4 Million SEK | 48.35% |
2021 Q4 | 45.37 Million SEK | 131.14% |
2021 Q3 | 19.63 Million SEK | -20.84% |
2021 Q2 | 24.79 Million SEK | 19.55% |
2020 FY | 67 Million SEK | 2020.95% |
2020 Q4 | 35.96 Million SEK | 183.45% |
2020 Q3 | 12.68 Million SEK | -13.47% |
2020 Q2 | 14.66 Million SEK | 46.38% |
2020 Q1 | 10.01 Million SEK | -55.94% |
2019 Q3 | 2.69 Million SEK | -39.47% |
2019 FY | 3.15 Million SEK | 0.0% |
2019 Q1 | 3.14 Million SEK | 0.0% |
2019 Q2 | 4.44 Million SEK | 41.26% |
2019 Q4 | 22.73 Million SEK | 745.09% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Acarix AB (publ) | 82.85 Million SEK | -95.999% |
ADDvise Group AB (publ) | 611.8 Million SEK | 73.458% |
ADDvise Group AB (publ) | 611.8 Million SEK | 73.458% |
Arcoma AB | 53.25 Million SEK | -204.937% |
Bactiguard Holding AB (publ) | 4.96 Million SEK | -3167.961% |
BICO Group AB (publ) | 2.84 Billion SEK | 94.299% |
Boule Diagnostics AB (publ) | 210.44 Million SEK | 22.837% |
CellaVision AB (publ) | 295.99 Million SEK | 45.138% |
Clinical Laserthermia Systems AB (publ) | 68.93 Million SEK | -135.58% |
Chordate Medical Holding AB (publ) | 1.3 Million SEK | -12303.537% |
C-Rad AB (publ) | 3.8 Million SEK | -4173.289% |
Duearity AB (publ) | 21.58 Million SEK | -652.305% |
Dignitana AB (publ) | 74.73 Million SEK | -117.278% |
Episurf Medical AB (publ) | 2.7 Million SEK | -5914.259% |
Getinge AB (publ) | 10.75 Billion SEK | 98.491% |
Scandinavian Real Heart AB (Publ) | 18.22 Million SEK | -790.827% |
Iconovo AB (publ) | 63.35 Million SEK | -156.312% |
Integrum AB (publ) | 90.57 Million SEK | -79.289% |
Luxbright AB (publ) | 23.09 Million SEK | -603.254% |
Mentice AB (publ) | 237.06 Million SEK | 31.5% |
OssDsign AB (publ) | 175.6 Million SEK | 7.526% |
Paxman AB (publ) | 133.8 Million SEK | -21.364% |
Promimic AB (publ) | 48.55 Million SEK | -234.456% |
SciBase Holding AB (publ) | 69.97 Million SEK | -132.058% |
ScandiDos AB (publ) | 61.03 Million SEK | -166.039% |
Sectra AB (publ) | 39.06 Million SEK | -315.7% |
Sedana Medical AB (publ) | 174.52 Million SEK | 6.958% |
Senzime AB (publ) | 141.51 Million SEK | -14.746% |
SpectraCure AB (publ) | 12.12 Million SEK | -1238.926% |
Stille AB | 87.21 Million SEK | -86.181% |
Vitrolife AB (publ) | 5.56 Billion SEK | 97.083% |
Xvivo Perfusion AB (publ) | 440.92 Million SEK | 63.172% |